Showing results (281-290 of 369) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman PrimatesDarren R Veach, Claire M Storey, Katharina Lückerath, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
JCO Clinical Cancer Informatics|January 19, 2019
Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate CancerMatthew D Galsky, Mohamed Shahin, Rachel Jia, et al.
JAMA Oncology|November 10, 2017
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate CancerJosef J Fox, Somali C Gavane, Estelle Blanc-Autran, et al.
JCO Precision Oncology|November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate CancerAndrew J Armstrong, Jun Luo, David M Nanus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.
European Urology|February 7, 2012
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan IndexDavid Ulmert, Reza Kaboteh, Josef J Fox, et al.
NPJ Precision Oncology|February 14, 2024
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapyCharlotte S Walmsley, Philip Jonsson, Michael L Cheng, et al.
Pageof 37